Propanc Biopharma (PPCB) Stock Price, News & Analysis

Company Overview

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth. Propanc has conducted toxicology studies and in vitro assessments to establish safety profiles and enzyme stability, and it continues to advance its candidates through formulation optimization and manufacturing scale-up. In parallel, Propanc explores potential combination regimens with established oncology drugs to support future clinical trial designs.

Headquartered in Perth, Western Australia, with additional research collaborations in North America, Propanc Biopharma serves a global oncology community through its development partnerships and licensing discussions. The company is governed by a board and executive team with experience in biotechnology, protein engineering and clinical development, and it aims to position its enzyme-based platform as a complementary approach to existing cancer therapies.

Key Stats

• Today's Range: $1.20 to $1.29
• 50-Day Range: $0.99 to $2.43
• 52-Week Range: $0.95 to $234.00
• Volume: 39,411 shs
• Average Volume: 155,670 shs
• Market Capitalization: $2.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Propanc Biopharma Stock Analysis - MarketRank™

Propanc Biopharma scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Propanc Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Propanc Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Propanc Biopharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Propanc Biopharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Propanc Biopharma has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.24% of the float of Propanc Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Propanc Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Propanc Biopharma has recently decreased by 84.91%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Propanc Biopharma does not currently pay a dividend.

Dividend Growth

Propanc Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.72

News Sentiment

Propanc Biopharma has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Propanc Biopharma this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Propanc Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.50% of the stock of Propanc Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Propanc Biopharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/15/2025
• Today: 8/16/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PPCB
• Previous Symbol: OTCMKTS:PPCB
• CIK: 1517681
• Web: www.propanc.com
• Phone: (139) 882-0780
• Fax: 61 03 9882 9969
• Employees: 1
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): ($24.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.92 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -151.28%
• Return on Assets: -109.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.37
• Quick Ratio: 2.37

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $29.94 per share
• Price / Book: 0.04

Miscellaneous

• Outstanding Shares: 2,280,000
• Free Float: 1,629,000
• Market Cap: $2.78 million
• Optionable: Not Optionable
• Beta: 3.52